furosemide has been researched along with Acromegaly in 8 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Acromegaly: A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The IGF-I-mediated and PTH-independent increase in calcitriol synthesis in acromegaly is responsible for both absorptive hypercalciuria and increased fasting plasma calcium linked to enhanced distal tubular calcium reabsorption, as shown by the selectively diminished calciuric response to furosemide." | 5.16 | Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? ( Azizi, M; Blanchard, A; Brailly-Tabard, S; Chanson, P; Gauci, C; Kamenický, P; Letierce, A; Lombès, M; Prié, D; Salenave, S; Souberbielle, JC, 2012) |
| "Sixteen patients (five females, 11 males) with acromegaly were randomly assigned to receive 20 mg amiloride (an ENaC blocker) and 25 mg furosemide (a Na-K-2Cl cotransporter blocker) under a high-sodium diet to suppress endogenous renin and aldosterone." | 5.15 | Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. ( Azizi, M; Blanchard, A; Chanson, P; Frank, M; Kamenicky, P; Letierce, A; Lombès, M; Salenave, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Izgi, C | 1 |
| Feray, H | 1 |
| Cevik, C | 1 |
| Saltan, Y | 1 |
| Mansuroglu, D | 1 |
| Nugent, K | 1 |
| Kamenicky, P | 2 |
| Blanchard, A | 2 |
| Frank, M | 1 |
| Salenave, S | 2 |
| Letierce, A | 2 |
| Azizi, M | 2 |
| Lombès, M | 2 |
| Chanson, P | 2 |
| Gauci, C | 1 |
| Brailly-Tabard, S | 1 |
| Prié, D | 1 |
| Souberbielle, JC | 1 |
| Karlberg, BE | 1 |
| Ottosson, AM | 1 |
| Goździk, J | 2 |
| Czekalski, S | 1 |
| Widecka, K | 1 |
| Verbanck, M | 1 |
| Futeral, B | 1 |
| Brauman, J | 1 |
| Ilunga, E | 1 |
| Cain, JP | 1 |
| Williams, GH | 1 |
| Dluhy, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physiopathology of Sodium Retention in Acromegaly[NCT00531908] | 12 participants (Actual) | Interventional | 2007-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for furosemide and Acromegaly
| Article | Year |
|---|---|
Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity.
Topics: Acromegaly; Aldosterone; Amiloride; Body Fluids; Cross-Over Studies; Diuretics; Edema; Epithelial So | 2011 |
Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria?
Topics: Acromegaly; Adult; Aged; Calcitriol; Calcium, Dietary; Diuretics; Female; Fibroblast Growth Factor-2 | 2012 |
6 other studies available for furosemide and Acromegaly
| Article | Year |
|---|---|
Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly.
Topics: Acromegaly; Cabergoline; Diuretics; Echocardiography, Doppler, Color; Ergolines; Female; Furosemide; | 2010 |
Acromegaly and hypertension: role of the renin-angiotensin-aldosterone system.
Topics: Acromegaly; Adult; Aged; Aldosterone; Blood Pressure; Female; Furosemide; Humans; Hypertension; Male | 1982 |
[Control of the quality of radioimmunological methods of determining plasma levels of atrial natriuretic peptide (ANP) and the evaluation of their usefulness in clinical studies].
Topics: Acromegaly; Adult; Atrial Natriuretic Factor; Blood Pressure; Diagnostic Errors; Female; Furosemide; | 1992 |
Effect of extracellular fluid volume contraction and expansion on plasma atrial natriuretic peptide (ANP) concentration in patients with acromegaly.
Topics: Acromegaly; Atrial Natriuretic Factor; Extracellular Space; Female; Furosemide; Humans; Male; Water- | 1989 |
[Diagnosis and treatment of hypercalcemia].
Topics: Acromegaly; Adrenal Insufficiency; Adult; Aged; Calcinosis; Calcitonin; Cortisone; Edetic Acid; Fema | 1973 |
Plasma renin activity and aldosterone secretion in patients with acromegaly.
Topics: Acromegaly; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Chlorides; Diet, | 1972 |